Abstract
Follicular lymphoma (FL) is incurable with the current standard therapeutic strategy despite improvements of the natural history of FL in the last few decades. For advanced-stage patients with low-tumor burden, watchful waiting remains the standard treatment. The optimal timing of rituximab monotherapy has not been elucidated. For advanced-stage patients with high-tumor burden, anti-CD20 monoclonal antibody and chemotherapy are the standard care. A subset of FL patients who had early progression of relapse within 24 months has a significantly poor prognosis. Among the early progression of the disease group, more early progression and transformation are important factors. Recently, genomic analysis suggests that high-risk biology may depend on the type of chemotherapy. Therefore, the genomic profile could help develop appropriate treatment selection in the future. This review includes the current FL treatment strategy and prognostic factors.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
